Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

CYP2D6 and tamoxifen: DNA matters in breast cancer.

Nature reviews. Cancer - 1 Aug 2009

Hoskins Janelle M, Carey Lisa A, McLeod Howard L

Abstract excerpt

Tamoxifen is the most widely used anti-oestrogen for the treatment of hormone-dependent breast cancer. The pharmacological activity of tamoxifen is dependent on its conversion by the hepatic drug-metabolizing enzyme cytochrome P450 2D6 (CYP2D6) to its abundant metabolite, endoxifen. Patients with reduced CYP2D6 activity, as a result of either their genotype or induction by the co-administration of drugs that...

Topics

Join the communities discussing this publication.

Antineoplastic Agents, Hormonal
Breast Neoplasms
Cytochrome P-450 CYP2D6
Drug Resistance, Neoplasm
Genotype

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Receptors, Estrogen

Source

Identifiers

PMID: 19629072
DOI: 10.1038/nrc2683

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

CYP2D6 and tamoxifen: DNA matters in breast cancer.PMID 19629072Read ↗

CYP2D6 polymorphisms and the impact on tamoxifen therapy.Semantic proximity Read ↗

Important and critical scientific aspects in pharmacogenomics analysis: lessons from controversial results of tamoxifen and CYP2D6 studies.Semantic proximity Read ↗

Pharmacogenomics toward personalized tamoxifen therapy for breast cancer.Semantic proximity Read ↗

CYP2D6 genotyping and tamoxifen: an unfinished story in the quest for personalized medicine.Semantic proximity Read ↗

Pharmacogenetics of tamoxifen: who should undergo CYP2D6 genetic testing?Semantic proximity Read ↗

Pharmacogenomics of breast cancer: highlighting CYP2D6 and tamoxifen.Semantic proximity Read ↗

Tamoxifen and CYP2D6: A Controversy in Pharmacogenetics.Semantic proximity Read ↗

Clinical Relevance of CYP2D6 Genetics for Tamoxifen Response in Breast CancerSemantic proximity Read ↗

Pharmacogenetics of endocrine therapy for breast cancer.Semantic proximity Read ↗

Clinical significance of CYP2D6 polymorphisms and tamoxifen in women with breast cancer.Semantic proximity Read ↗

Tamoxifen metabolism and its effect on endocrine treatment of breast cancer.Semantic proximity Read ↗

CYP2D6 testing in breast cancer: ready for prime time?Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.